Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)

This study is investigating how the immune system responds to infections and cancer in two groups: people receiving certain cancer immunotherapy treatments, and people with primary liver tumors. It aims to build a better understanding of immune function to improve care. **You may be eligible if...** - For Group 1 (immunotherapy patients): You are over 18, you are receiving immunotherapy and have no active cancer or autoimmune disease, and you do not have HIV, hepatitis C, or hepatitis B - For Group 2 (liver tumor patients): You are over 18 and have a primary liver tumor **You may NOT be eligible if...** - Group 1: You have an active or past cancer, autoimmune disease, HIV, HCV, or HBV infection, or diabetes - Group 2: You have other cancers outside the liver in the past 3 years, chronic autoimmune diseases, life expectancy under 12 months, or are receiving specific cancer drugs (such as atezolizumab, sorafenib, or checkpoint inhibitors) Talk to your doctor to see if this trial is right for you.